Oncologists’ Guide to the FDA Approval of Tafasitamab for Relapsed FL

The recent FDA approval of tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) and rituximab (Rituxan) for relapsed/refractory follicular lymphoma marks a significant advancement in the management of this often relapsing, yet indolent, B-cell malignancy. This chemotherapy-free triplet regimen, supported by the robust findings from the inMIND trial (NCT04680052), offers oncologists a new, highly effective, and well-tolerated option for their patients, particularly those with high-risk disease.¹